QUT offers a diverse range of student topics for Honours, Masters and PhD study. Search to find a topic that interests you or propose your own research topic to a prospective QUT supervisor. You may also ask a prospective supervisor to help you identify or refine a research topic.

Filter by faculty:

Found 2 matching student topics

Displaying 1–2 of 2 results

Eribulin effects on epithelial mesenchymal plasticity and therapy response

Epithelial mesenchymal plasticity (EMP) is a highly regulated and powerful cellular process that is fundamental in embryonic development (1), which is hijacked by cancer cells for metastatic progression and therapy resistance in epithelial cancers (2). Eribulin is a microtubule-inhibiting cancer drug discovered in sea sponges and approved for 3rd line therapy in metastatic breast cancer, which was shown to block EMP (3).We hypothesise that eribulin’s reversal of EMT will sensitise breast cancer cells to other therapies and ultimately improve patient …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Reversing Epithelial Mesenchymal Plasticity with Eribulin to Enhance Therapy Response

Epithelial mesenchymal plasticity (EMP) is a highly regulated and powerful cellular process that is fundamental in embryonic development (1), which is hijacked by cancer cells for metastatic progression and therapy resistance in epithelial cancers (2). Eribulin is a microtubule-inhibiting cancer drug discovered in sea sponges and approved for 3rd line therapy in metastatic breast cancer, which was shown to reverse epithelial mesenchymal transition (EMT) (3).We hypothesise that eribulin’s reversal of EMT will sensitise breast cancer cells to other therapies and …

Study level
Master of Philosophy
Faculty
Faculty of Health
School
School of Biomedical Sciences

Page 1 of 1

Contact us

If you have questions about the best options for you, the application process, your research topic, finding a supervisor or anything else, get in touch with us today.